Dare Bioscience Inc expected to post a loss of 14 cents a share - Earnings Preview

Dare Bioscience

28/03/2023 14:07

* Dare Bioscience Inc  DARE.OQ   DARE.O  is expected to show
no
change in quarterly revenue when it reports  results on March
30. 
    * 
    * ​Refinitiv's mean analyst estimate for Dare Bioscience Inc
is
for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Dare
Bioscience
Inc is $6​, above​ its last closing price of $1.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.11       -0.12      -0.08     Beat    31.9
 Jun. 30 2022  -0.06       -0.06      0.00      Beat    100
 Mar. 31 2022  -0.14       -0.14      -0.10     Beat    29.8​
 Dec. 31 2021  -0.20       -0.15      -0.18     Missed  -23.3
 ​​Sep.        -0.08       -0.13      -0.18     Missed  -35.8
 30 2021                                                
 Jun. 30 2021  -0.16       -0.16      -0.18     Missed  -14.3​
 Mar. 31 2021  -0.27       -0.22      -0.17     Beat    23.6
 Dec. 31 2020  -0.16       -0.13      -0.28     Missed  -122.2
 This summary was machine generated March 28 at 13:07 GMT.  All
figures in US dollars  unless otherwise stated